Eye Tech Care has closed a funding and partnership agreement with Everpine Capital, a Chinese investor, according to a press release. Under the partnership, Everpine will invest a total of €25 million and support Eye Tech Care in its international expansion.
It is with immense sadness that the Asia-Pacific Academy of Ophthalmology announces the passing of Hyung-Woo Kwak, MD, PhD, president-elect of the Asia-Pacific Academy of Ophthalmology, vice president of the Asia-Pacific Vitreo-retina Society and counc…
At OSN New York 2015, Parag A. Majmudar, MD, discusses the advantages of the femtosecond laser for astigmatism correction.
LYON, France–(BUSINESS WIRE)–EYE TECH CARE SA, a French company developing and marketing equipment for non-invasive glaucoma treatment in ophthalmology, today announced that it has secured a new round of funding with a Chinese investor. EVERPINE Capital will invest in two rounds for a total amount of around 25 million euros and will support EYE TECH CARE in its international expansion. The company will benefit from EVERPINE Capital’s presence in China in order to further continue product regi
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, today provided an update on several key performance metrics, demonstrating the Company’s continued progress in executing its near- and long-term goals. Business Highlights as of December 31, 2015: Implanted 21 Argus® II Retinal Prosthesis Systems worldwide du
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Jonathan H. Talamo, M.D. to the position of Chief Medical Officer. In this role, Dr. Talamo will help advance Ocular’s development pipeline, including lead therapeutic candidate, DEXTENZATM. “Jonathan brings a wealth of expertise to Ocular during an